Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pityriasis Rosea Shortly After mRNA-1273 COVID-19 Vaccination

2 Nov 2021

Abstract excerpt

With the increase in rates of vaccination against COVID-19, various cutaneous reactions have been reported after vaccination, including pityriasis rosea (PR) (Catala et al., 2021; Johansen et al., 2021; Marcantonio-Santa Cruz et al., 2021; McMahon et al., 2021). It is easy to overlook because the incidence of PR as a side effect of COVID-19 vaccination is extremely low, accounting for about 0.96% of all cutaneous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to Dermatological and COVID-19 studies
Share to Herpesvirus Infections and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34740803
DOI: 10.1016/j.ijid.2021.10.055

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pityriasis Rosea Shortly After mRNA-1273 COVID-19 VaccinationPMID 34740803Read ↗

Clinical and immunological data from chronic urticaria onset after mRNA SARS‐CoV‐2 vaccinesSemantic proximity Read ↗

SARS‐CoV‐2 as possible inducer of viral reactivationsSemantic proximity Read ↗

Cutaneous Reactions after COVID-19 Vaccines – Analysis of the Clinical and Histological Spectrum – Case Series and Review of the LiteratureSemantic proximity Read ↗

Target Trial Emulation to Assess the Efficacy of the MVA-BN Vaccine as a Pre-Exposure Strategy in Individuals with Risk Factors for MpoxSemantic proximity Read ↗

Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from GreeceSemantic proximity Read ↗

A case series of interesting mucocutaneous presentations in COVID-19 infection or post COVID-19 vaccination confirmed by biopsy and histopathologic assessmentSemantic proximity Read ↗

Adverse Reaction to COVID-19 mRNA Vaccination in a Patient With VEXAS SyndromeSemantic proximity Read ↗

A randomized double-blind Phase IIb trial to evaluate the efficacy of ChAd63-KH for the treatment of post kala-azar dermal leishmaniasisSemantic proximity Read ↗

Rapid Progressive Systemic Sclerosis Following mRNA COVID-19 VaccinationSemantic proximity Read ↗

Immune Characteristics and HLA Associations of SARS-Cov-2 Vaccines-induced Delayed-Type Cutaneous Adverse ReactionsSemantic proximity Read ↗

Phenotypic spectrum of serious cutaneous-only adverse event following immunization with COVID-19 vaccines: a multicentre case series and literature review.Semantic proximity Read ↗

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, EnglandSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.